Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial-Reference-Cited by-同舟云学术

Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial

Published:2018-04 Issue:4 Volume:5 Page:e170-e180
ISSN:2352-3026
Container-title:The Lancet Haematology
language:en
Short-container-title:The Lancet Haematology

Author:

Brown Jennifer R,Hamadani Mehdi,Hayslip John,Janssens Ann,Wagner-Johnston Nina,Ottmann Oliver,Arnason Jon,Tilly Hervé,Millenson Michael,Offner Fritz,Gabrail Nashat Y,Ganguly Siddhartha,Ailawadhi Sikander,Kasar Siddha,Kater Arnon P,Doorduijn Jeanette K,Gao Lei,Lager Joanne J,Wu Bin,Egile Coumaran,Kersten Marie José

Publisher

Elsevier BV

Subject

Hematology

Reference26 articles.

1. Novel treatments for chronic lymphocytic leukemia and moving forward;Brown;Am Soc Clin Oncol Educ Book,2014

2. PIK3CA mutations are mutually exclusive with PTEN loss in diffuse large B-cell lymphoma;Abubaker;Leukemia,2007

3. Mutations driving CLL and their evolution in progression and relapse;Landau;Nature,2015

4. Integrative genomic analysis implicates gain of PIK3CA at 3q26 and MYC at 8q24 in chronic lymphocytic leukemia;Brown;Clin Cancer Res,2012

5. Phosphatidylinositol 3'-kinase catalytic subunit alpha gene amplification contributes to the pathogenesis of mantle cell lymphoma;Psyrri;Clin Cancer Res,2009

Cited by 46 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Targeting PI3K family with small-molecule inhibitors in cancer therapy: current clinical status and future directions;Molecular Cancer;2024-08-10

2. Telomere-related DNA damage response pathways in cancer therapy: prospective targets;Frontiers in Pharmacology;2024-06-07

3. Molecular Targeting of the Phosphoinositide-3-Protein Kinase (PI3K) Pathway across Various Cancers;International Journal of Molecular Sciences;2024-02-06

4. Advancements in dual-target inhibitors of PI3K for tumor therapy: Clinical progress, development strategies, prospects;European Journal of Medicinal Chemistry;2024-02

5. Differentiation-inducing factor-1 reduces lipopolysaccharide-induced vascular cell adhesion molecule-1 by suppressing mTORC1-S6K signaling in vascular endothelial cells;Life Sciences;2023-12